98%
921
2 minutes
20
Objective: Patients with glioblastoma (GBM) often undergo surgery to prolong survival. However, the use of surgery, and more specifically achieving gross total resection (GTR), in patients >80 years old has yet to be fully assessed. Using the Surveillance, Epidemiology, and End Results (SEER) database, we aim to assess the efficacy of surgical resection, radiotherapy (RT) and chemotherapy (CT) on overall survival (OS) in very elderly GBM patients compared to elderly counterparts (age 65-79 years).
Methods: The SEER database was queried for all patients >65 years old with GBM (2000-2020). Patients not undergoing surgery or biopsy were excluded. Patients were stratified by age, and demographic relationships were assessed with chi-squared testing for categorical variables. Bivariable models were created using Kaplan-Meier survival estimates. All significant variables from bivariable analysis were included on multivariable Cox survival regression models to determine independent associations between clinical variables and OS.
Results: A total of 27,090 operative GBM patients were identified; 1868 patients (15.92 %) were very elderly and 10,092 patients (84.38 %) were elderly. Very elderly patients were less likely to undergo GTR (28 % vs 35 %, p<0.001), RT (59 % vs 78 %, p<0.001) and CT (40 % vs 66 %, p<0.001). In multivariable Cox regression analysis, very elderly patients who achieved GTR (HR=.696, p<0.001), received RT (HR=0.583, p<0.001) and underwent CT (HR=0.4197, p<0.001) had significantly improved OS compared to very elderly patients that did not undergo these treatment options.
Conclusion: Currently, very elderly GBM patients undergo lower rates of aggressive surgery, RT and CT. However, very elderly patients that undergo surgery, RT and CT may have a survival advantage. These treatments should be considered as potential options for this patient population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.clineuro.2024.108469 | DOI Listing |
J Eval Clin Pract
September 2025
Department of General Medicine, Osaka Medical and Pharmaceutical University Hospital, Takatsuki, Osaka, Japan.
Rationale: Physicians sometimes encounter various types of gut feelings (GFs) during clinical diagnosis. The type of GF addressed in this paper refers to the intuitive sense that the generated hypothesis might be incorrect. An appropriate diagnosis cannot be obtained unless these GFs are articulated and inventive solutions are devised.
View Article and Find Full Text PDFJ Patient Saf
September 2025
The Wellbeing Services County of Ostrobothnia, Vaasa, Finland.
Objectives: The aim of this study was to explore contributing factors identified in serious incident investigations conducted by internal, independent multidisciplinary teams.
Methods: A total of 166 serious incident investigation reports, conducted between 2018 and 2023 in 11 integrated social and health care organizations in Finland, were analyzed. The reports were classified by incident type and contributing factor, which were analyzed using the WHO's Conceptual Framework for the International Classification for Patient Safety.
J Eval Clin Pract
September 2025
Cochrane Taiwan, Taipei Medical University, Taipei, Taiwan.
Background: Chest radiography is often performed preoperatively as a common diagnostic tool. However, chest radiography carries the risk of radiation exposure. Given the uncertainty surrounding the utility of preoperative chest radiographs, physicians require systematically developed recommendations.
View Article and Find Full Text PDFPharmacotherapy
September 2025
Department of Biomedical Informatics, School of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Background: Omeprazole, a widely used proton pump inhibitor, has been associated with rare but serious adverse events such as myopathy. Previous research suggests that concurrent use of omeprazole with fluconazole, a potent cytochrome P450 (CYP) 2C19/3A4 inhibitor, may increase the risk of myopathy. However, the contribution of genetic polymorphisms in CYP enzymes remains unclear.
View Article and Find Full Text PDFGenet Med
September 2025
Division of Medical Genetics, University of Washington School of Medicine.
Purpose: The fourth phase of the Electronic Medical Records and Genome Network (eMERGE4) is testing the return of 10 polygenic risk scores (PRS) across multiple clinics. Understanding the perspectives of health-system leaders and frontline clinicians can inform plans for implementation of PRS.
Methods: Fifteen health-system leaders and 20 primary care providers (PCPs) took part in semi-structured interviews.